Bridging the gap between complementary and conventional medical approaches for harmonious integration and patient benefit.In 2022, 80% (8/10) of my natural fertility clients gave birth to healthy babies, 100% ( 5/5) that were about to start IVF conceived naturally and gave birth . This is compared to IVF success rates of less than 30%. I translate 20+ years of Biomedical Genetic research insight of long term chronic conditions, into my therapy practice, harnessing Nutritional Genetics and lifestyle to provide targeted treatment plans for health and wellbeing. My Declaration published on NHS England news bulletin in 2016 for commitment to improving patient quality of life for long term conditions. Modalities include Nutritional Genetics, Functional (Lifestyle) Medicine and Reflexology.Clients include Local Authority, Mersey NHS Trust, BUPA and Barchester care homes, private and corporate groups and individual 1:1s.Committed to Continued Professional Development, deepening my understanding on a daily basis !Specialities include Reflexology for Lymph Drainage (RLD)Adapted ReflexTherapy for spinal injury and whiplash (AdRx)Reproductive Reflexology Nutritional GeneticsOptimum Health Coaching, including anti-inflammatory and immune support protocols Mind-body connection to health and wellbeingBio-hackingLongevity Dale Bredesen's reversing Alzheimers workshopI volunteer at Macclesfield Cancer Help Centre and attend numerous patient support groups. I write regular health articles for Local People magazine with a distribution of 37,000. Some are featured on my website http://toptotoetreatments.com/

Enabling projects to meet EMA regulatory guidelines and personalised medicine strategies as early in the drug development pipeline as practical. Ensuring appropriate genetic considerations have been factored into study design to determine effect of genetics on drug disposition and avoiding potentially costly delays in projects later.

Authored the AstraZeneca Pharmacogenetics Strategy, enabling project leaders to meet EMA/CHMP/37646/2009 regulations & aligning with the AZ Personalised Healthcare Strategy. Signed off by global leaders. Implemented Aug. 2012. Expertise in the Genetics of Absorption, Distribution, Metabolism and Excretion for drug response and personalised medicine. Produced standardised genotyping algorithms & decision trees, for genes involved in ADME, to guide project leaders in design & interpretation of pre-clinical studies to assess the effect of genetics to meet regulatory pharmacogenetic guidelines for drug development.Engaged with FDA via AZ Regulatory Affairs, providing comments during consultation to shape their PGx guidance, gaining favourable response from FDA on their website . Established a central repository of regulatory guidances, company international procedures & local SOPs to guide compliance within my function.Evaluated the AffymetrixDMETplus genotyping chip technology for analysis, interpretation & outsource management.Co-developed and supervised a PhD project on the genetics of Vitamin B12 deficiency with Metformin.Initiated and ran monthly Global Webinars for the multi-functional teams involved in the development and delivery of companion diagnostics. Facilitated Results Orientated Management (ROM) to the Tablets Formulation Leadership Team, during business transition.Presented seminars & posters at International conferences; PGx Hinxton and ISSX Istanbul.

Disease Gene Mapping and Genetics of Drug Response. Identified the causative gene SCN9A for congenital insensitivity to pain, validating this as a suitable analgesic drug target. Identifying and mapping genes with Bio informatics during the genome mapping era.Discovery of mutations and genes implicated in Osteo-Arthtritis

A founder member of the Global R&D Genetics Department. Research included exon trapping, gene mapping, polygenic disorders including Bi-Polar Disorder, OsteoArthritis, Schizophrenia.

Mapping the Ataxia-Telangiectasia (ATM) gene , restriction enzyme mapping, yeast artificial chromosomes.